This article is more than 5 years old. Information may no longer be current.
VIDEO: Additional treatment with ALK inhibitor after progression shows promise in non-small cell lung cancer
Click Here to Manage Email Alerts
CHICAGO — Ensartinib shows promise for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, Makenzi Evangelist, MD, said at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.
Leora Horn, MD, MSc, and colleagues evaluated ensartinib (X-396, Xcovery) — a novel, potent ALK small molecule tyrosine kinase inhibitor — in patients with advanced solid tumors.
Among 22 patients with ALK-positive NSCLC, five (26%) achieved a partial response and six (32%) achieved stable disease for a disease control rate of 58%.
“We’re seeing really good responses from additional treatment after progression on our second generation ALK inhibitor,” Evangelist, from New York Oncology Hematology, said. “So, this is showing promise, and further enrollment is currently underway.” – by Kristie L. Kahl
Reference:
Horn L, et al. Abstract OA03.08. Presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology; Sept. 14-16, 2017; Chicago.
Disclosure: Evangelist reports no relevant financial disclosures.